echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > NEJM Blockbuster of the Year! A comprehensive review of recent developments in the treatment of hepatitis B

    NEJM Blockbuster of the Year! A comprehensive review of recent developments in the treatment of hepatitis B

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎WuXi AppTec content team editor


    Chronic hepatitis B infection remains a significant global public health burden
    .
    Globally, an estimated 296 million people live with chronic hepatitis B, of whom 221 million live in countries or regions
    with medium/low levels of economic development.
    Without effective intervention for patients with chronic hepatitis
    B, it is expected that by 2035, the number of deaths due to hepatitis B virus infection may peak
    at 1.
    14 million.


    Recently, the New England Journal of Medicine (NEJM), a top international medical journal, published its annual blockbuster review "Innovative Therapies for Hepatitis B", detailing the latest progress
    in the research of new biomarkers and innovative drugs in the field of hepatitis B diagnosis and treatment.


    Screenshot source: NEJM


    Novel diagnostic markers



    At present, the commonly used markers for the diagnosis and treatment of patients with chronic hepatitis B include hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis B core antibody (anti-HBc) and hepatitis B virus DNA.

    The review notes that the persistence of intrahepatic covalently closed circular DNA (cccDNA) is the main cause of chronicization of HBV infection, however, HBsAg testing such as HBsAg does not distinguish between HBsAg derived from cccDNA and HBsAg
    derived from integrated viral genomes.


    At present, there is still a lack of recognized quantitative detection standards for cccDNA, but a variety of liver tissue cccDNA quantitative detection technologies are in the research and development stage
    .
    In addition, two novel serum markers, HBV
    RNA and hepatitis B core-associated antigen (HBcrAg), have been used to assess the transcriptional activity
    of cccDNA.


    • HBV RNA:


    During HBV replication, a small number of pregenomic RNAs (pgRNAs) release HBV-containing capsids into serum
    .
    At present, scientists have developed two high-throughput detection methods for the quantitative detection of pgRNA
    .
    It should be pointed out that HBeAg-positive patients have significantly increased HBV RNA levels; In HBeAg-negative patients, there was a poor correlation between HBV RNA levels and HBsAg levels (because HBsAg was derived from the integrated genome).

    Because nucleoside analogues of standard therapy for hepatitis B have minimal effect on cccDNA transcription to pgRNA, HBV RNA can be detectable for years
    during hepatitis B treatment.


    • HBcrAg:


    HBcrAg testing involves HBeAg, HBcAg, and p22cr proteins (i.
    e.
    , the detection component is only from HBV cccDNA).

    At present, scientists have developed a more sensitive serum HBcrAg detection technology, which has a detection limit of 2.
    1 log10U/ml
    .


    The review notes that both HBV RNA and HBcrAg assays identify active cccDNA transcription, so these two tests may identify patients at higher risk of disease progression and predict the likelihood
    of relapse after discontinuation of drug therapy.
    These two markers are expected to overcome the limitations of quantitative HBsAg, HBV DNA, and HBeAg detection, and effectively distinguish HBeAg-negative patients from patients with less active infection
    .


    ▲ Hepatitis B virus survival cycle (Image source: Reference [1]).


    Innovative therapies for hepatitis B



    The goal of treatment for hepatitis B is to achieve a functional cure, i.
    e.
    , persistent loss of HBsAg (below the detection limit of 0.
    05 IU/ml) after discontinuation of drug therapy, and no detectable
    presence of HBV DNA in serum.
    The review highlights that
    three goals need to be achieved to truly cure hepatitis B infection:


    • eradication, degradation or silencing of cccDNA;

    • silencing integrated viral genomes;

    • Corrects antigen-specific immune dysfunction
      .


    At present, the frontier of hepatitis B treatment includes viral entry inhibitors, RNA disruptors (siRNA), HBsAg assembly agents, capsid protein assembly modulators (CAM) and immunomodulatory therapies.


    • Viral entry inhibitors:


    Bulevirtide is an HBV/HDV viral entry inhibitor that binds to and inactivates sodium taurocholate co-transporting polypeptides, thereby inhibiting hepatitis B virus and hepatitis D virus entry into hepatocytes
    .
    At present, the therapeutic effect of this drug in chronic hepatitis B is still in
    the early stage of clinical exploration.


    • Nucleic acid polymers:


    Nucleic acid polymers such as REP 2139 block the assembly and secretion
    of HBV subviral particles.
    Scientists have evaluated the efficacy
    of REP 2139 in combination therapies such as tenofovir or peginterferon.
    The study showed that
    after 48 weeks of follow-up, 14 of the 40 patients treated with REP 2139 tested negative for HBsAg
    .


    • Capsid protein assembly regulator (CAM):


    A variety of oral small molecule CAMs are currently in the research and development stage
    .
    These drugs disrupt pgRNA capsidization
    by interfering with capsid assembly.
    Studies have shown that
    these drugs can reduce serum HBV DNA levels by up to 4 log 10 IU/ml and HBV RNA levels by up to 3 log10copies/ml
    within 28 days.


    • RNA interferents:


    RNA disruptors include siRNA and antisense oligonucleotides (ASOs).

    Among them, siRNA lasts longer
    than ASO.


    The results of phase 1 and phase 2 trials showed that 60%~75% of patients receiving siRNA treatment had a reduction of HBsAg of more than 2.
    0 log 10 IU/ml within 24~48 weeks, and the HBsAg level was less than100IU/ml, while the rebound after treatment was relatively slow
    .


    ASO are synthetic single-stranded oligonucleotides that bind to complementary HBV RNA transcripts to form hybrid ASO-RNA
    complexes.
    Results from a recent Phase 2b b-Clear study showed that
    10% of patients with chronic HBV infection who received monotherapy with the antisense oligonucleotide bepirovirsen met the primary endpoint (i.
    e.
    , HBsAg levels below the detection limit of 0.
    05 IU/ml within 24 weeks of discontinuation; HBV DNA levels below 20 IU/ml).


    Image source: 123RF


    Although these innovative therapies have not yet achieved the primary goal of functional cure, data from these clinical studies also show that most patients are on track to achieve the goal
    of reducing HBsAg levels to less than 100 IU/ml with these innovative therapies.
    Based on the current treatment progress, many experts have proposed the concept of "partial functional cure" (that is, the HBsAg level drops to <100 IU/ml within 6 months of limited treatment).
    <b20>


    The review points out that there are still a number of innovative therapies in the preclinical research stage, including hepatitis B X gene targeted therapy, cccDNA destabilization therapy, CRISPR-Cas9 gene editing therapy (edit cccDNA), etc
    .
    In addition, early research data suggest that the use of novel antivirals alone is not sufficient to restore effective immunomodulatory capacity
    in patients with hepatitis B.
    Therefore, in the field of hepatitis B treatment, the research of immunomodulatory drugs (such as peginterferon α, oral selective toll-like receptor agonists) is also a hot spot
    .



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.